Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis

Kidney International

Volumn 60, Issue 2, 2001, Pages 653-663

  Zoja, Carla ^a   Benigni, Ariela ^a   Noris, Marina ^a   Corna, Daniela ^a   Casiraghi, Federica ^a   Pagnoncelli, Marcella ^a   Rottoli, Daniela ^a   Abbate, Mauro ^a   Remuzzi, Giuseppe ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

Anti inflammatory; Autoimmune disease; DFU; Immunosuppression; Inflammation; Nephrotoxicity; Progressive nephritis

Indexed keywords

3 (3 FLUOROPHENYL) 5,5 DIMETHYL 4 (4 METHYLSULFONYLPHENYL) 2(5H) FURANONE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DRUG VEHICLE; MESSENGER RNA; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; DRUG INDICATION; DRUG MIXTURE; FEMALE; LUPUS ERYTHEMATOSUS NEPHRITIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; SURVIVAL; UREA NITROGEN BLOOD LEVEL;

EID: 0034927121     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2001.060002653.x     Document Type: Article

References (41)

1. The immunology and pathology of NZB mice
2. Relevance of systemic lupus erythematosus nephritis animal models to human disease
3. Nephritogenic autoantibodies in lupus: Current concepts and continuing controversies
4. Lupus nephritis: Update on pathogenesis and disease mechanisms
5. Role of nucleosomes for induction and glomerular binding of autoantibodies in lupus nephritis
6. Treatment of lupus nephritis
7. Mycophenolate mofetil, a rationally designed immunosuppressive drug
8. Mycophenolate mofetil in renal transplantation: Results from the U.S. randomized trials
9. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection
10. Mycophenolate mofetil in renal allograft recipients
11. Therapy of rheumatoid arthritis with mycophenolate mofetil
12. Mycophenolate mofetil for systemic vasculitis and IgA nephropathy
13. Mycophenolate mofetil for the treatment of Takayasu arteritis: Report of three cases
14. Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease
15. Attenuation of murine lupus nephritis by mycophenolate mofetil
16. Renal expression of monocyte chemoattractant protein-1 in lupus autoimmune mice
17. 1pr mice
18. Increased renal thromboxane production in murine lupus nephritis
19. 2 production in patients with systemic lupus erythematosus
20. Long-term thromboxanesynthase inhibition prolongs survival in murine lupus nephritis
21. Improvement of renal function with selective thromboxane antagonism in lupus nephritis
22. Cyclooxygenase in biology and disease
23. Cyclooxygenase-2 in the kidney
24. Cyclooxygenase-2 inhibition decreases renin content and lowers blood pressure in a model of renovascular hypertension
25. Furosemide stimulates macula densa cyclooxygenase-2 expression in rats
26. Upregulation of renal and systemic cyclooxygenase-2 in patients with active lupus nephritis
27. COX-2 inhibitors
28. Selective increase of cyclooxygenase-2 expression in a model of renal ablation
29. A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats
30. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor
31. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
32. Therapeutic studies in NZB/W mice. III. Relationship between renal status and efficacy of immunosuppressive drug therapy
33. Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease
34. Minimization of variation in the response to different proteins of the Coomassie blue G dye-binding assay for protein
35. 2 synthesis induced by cyclosporin A
36. Thromboxane augmentation of alloreactive T cell function
37. Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide
38. Mycophenolate mofetil therapy in lupus nephritis: Clinical observations
39. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis
40. Renal effects of nonsteroidal anti-inflammatory drugs in chronic glomerular disease
41. Induction of cyclooxygenase-2 on activated T lymphocytes: Regulation of T cell activation by cyclooxygenase-2 inhibitors